Category: Parkinson's Disease: Neuroimaging
Objective: To compare the performance of [18F]fluorodeoxyglucose (FDG) PET and [123I]metaiodobenzylguanidine (MIBG) scintigraphy in the differential diagnosis of parkinsonism in the same patient sample.
Background: [18F]fluorodeoxyglucose (FDG) PET and [123I]metaiodobenzylguanidine (MIBG) scintigraphy are recommended in the current consensus criteria for the differential diagnosis of neurodegenerative parkinsonism. A direct comparison of both methods is lacking.
Method: 54 patients of three tertiary referral centers who underwent [18F]FDG PET and [123I]MIBG scintigraphy in the differential diagnosis of suspected atypical parkinsonian syndrome (APS) were included in this study. Clinical follow-up diagnoses were made based on case-vignettes by two movement disorder specialists, blinded to imaging results. [18F]FDG PET scans were evaluated by two raters for disease-specific patterns of Lewy body disease (LBD) or APS. The latter were also assigned to the subgroups of APS. Regions-of-interest analysis on late anterior planar [123I]MIBG images was used to calculate heart-to-mediastinum ratio.
Results: Clinical follow-up diagnoses were n=19 LBD (n = 17 Parkinson’s disease (PD); n=1 PD dementia, N=1 dementia with Lewy bodies), n = 31 APS (n = 28 MSA, n = 3 PSP), n = 3 non-neurodegenerative parkinsonism; n = 1 patient could not be diagnosed and was excluded. For the differentiation of LBD vs. non-LBD the area under the receiver operating characteristic curve (ROC-AUC) was larger for [18F]FDG PET than for [123I]MIBG scintigraphy at trend level (0.82 vs. 0.69, p = 0.06) (see fig 1a) and reached significance for the more experienced rater (0.83 vs. 0.69, p = 0.04). ROC-AUC for the differentiation of PD vs MSA was greater for [18F]FDG PET than for [123I]MIBG scintigraphy (0.82 vs. 0.69, p = 0.11) (fig 1b), but failed to reach statistical significance. [18F]FDG PET and clinical diagnoses matched in 87.1% of APS cases.
Conclusion: The present study suggests that [18F]FDG PET is superior to [123I]MIBG scintigraphy in the differential diagnosis of neurodegenerative parkinsonism and provides additional information in the delineation of APS subgroups. Therefore, [18F]FDG PET should be preferred for this purpose.
Figure 1 Receiver operating characteristic (ROC) curves for the A) differentiation of Lewy body diseases from non-Lewy body diseases and B) differentiation of Parkinson’s disease from multiple system atrophy.
References: This abstract has been submitted for presentation at: 58. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin, Leipzig, Germany, April 22nd-25th 2020; 64. Jahrestagung der Deutschen Gesellschaft für Klinische Neurophysiologie und Funktionelle Bildgebung, Baden Baden, Germany, March 26th-28th 2020
To cite this abstract in AMA style:N. Schröter, J. Brumberg, G. Blazhenets, L. Frings, J. Volkmann, C. Lapa, W. Jost, I. Isaias, P. Meyer. FDG PET and MIBG scintigraphy in the differential diagnosis of parkinsonism: a head-to-head comparison [abstract]. Mov Disord. 2020; 35 (suppl 1). https://www.mdsabstracts.org/abstract/fdg-pet-and-mibg-scintigraphy-in-the-differential-diagnosis-of-parkinsonism-a-head-to-head-comparison/. Accessed December 7, 2023.
« Back to MDS Virtual Congress 2020
MDS Abstracts - https://www.mdsabstracts.org/abstract/fdg-pet-and-mibg-scintigraphy-in-the-differential-diagnosis-of-parkinsonism-a-head-to-head-comparison/